Highline Sciences Acquired by Tempus

KO client Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology, has been acquired by Tempus. The KO team, led by attorneys Samantha Pjesky, Jon Taylor and Ryan Ivey, represented Highline in this acquisition.

Tempus is a leader in artificial intelligence and precision medicine. With this acquisition, Tempus will be able to vertically integrate more clinical trial services.

“We are thrilled to join a mission-driven organization that is aligned with our values and our focus on making a positive difference in the lives of patients,” said Collin Williams, Founder and CEO of Highline Sciences. “Joining forces with Tempus creates a unique offering for customers and new, innovative approaches to improving clinical research services and accelerating the development of promising therapies.”

Read more about the acquisition in Fierce Healthcare.